Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1990 Sep;81(3):428–434. doi: 10.1111/j.1365-2249.1990.tb05351.x

IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic Ps. aeruginosa infection investigated by ELISA.

T Pressler 1, S S Pedersen 1, F Espersen 1, N Høiby 1, C Koch 1
PMCID: PMC1534976  PMID: 2118845

Abstract

ELISAs using subclass-specific monoclonal antibodies were developed for the quantification of human IgG1, IgG2, IgG3 and IgG4 antibodies to Ps. aeruginosa. We investigated the pattern of IgG subclass antibodies against Ps. aeruginosa in serum from patients with cystic fibrosis (CF), other patients with chronic Ps. aeruginosa infection, and healthy controls. Healthy controls and patients with CF but without Ps. aeruginosa infection showed no or very low titres of antibodies against Ps. aeruginosa. In the early stage of chronic Ps. aeruginosa infection, antibody titres in all four subclasses were significantly higher than either normals or CF patients without infection. Other patients with Ps. aeruginosa infection showed the same increased level of IgG subclass antibodies as CF patients in an early stage of infection. Sixteen patients (eight in good and eight in poor clinical condition) have been followed for an average of 13 years with multiple serum samples covering the pre-infection, early and late stages of chronic infection. Patients in a poor clinical condition showed significantly higher levels of IgG3 antibodies in the first year of infection and 2 years later also had significantly higher IgG2 antibody levels. We conclude that elevated levels of IgG2 and IgG3 antibodies to Ps. aeruginosa are a sign of poor prognosis in CF.

Full text

PDF
429

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander M. D., Andrews J. A., Leslie R. G., Wood N. J. The binding of human and guinea-pig IgG subclasses to homologous macrophage and monocyte Fc receptors. Immunology. 1978 Jul;35(1):115–123. [PMC free article] [PubMed] [Google Scholar]
  2. Barrett D. J., Ayoub E. M. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol. 1986 Jan;63(1):127–134. [PMC free article] [PubMed] [Google Scholar]
  3. Corey M., Levison H., Crozier D. Five- to seven-year course of pulmonary function in cystic fibrosis. Am Rev Respir Dis. 1976 Dec;114(6):1085–1092. doi: 10.1164/arrd.1976.114.6.1085. [DOI] [PubMed] [Google Scholar]
  4. Fick R. B., Jr, Naegel G. P., Matthay R. A., Reynolds H. Y. Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay. J Clin Invest. 1981 Oct;68(4):899–914. doi: 10.1172/JCI110345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fick R. B., Jr, Naegel G. P., Squier S. U., Wood R. E., Gee J. B., Reynolds H. Y. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest. 1984 Jul;74(1):236–248. doi: 10.1172/JCI111407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fick R. B., Jr, Olchowski J., Squier S. U., Merrill W. W., Reynolds H. Y. Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide. Am Rev Respir Dis. 1986 Mar;133(3):418–422. doi: 10.1164/arrd.1986.133.3.418. [DOI] [PubMed] [Google Scholar]
  7. Forsgren A., Sjöquist J. "Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin. J Immunol. 1966 Dec;97(6):822–827. [PubMed] [Google Scholar]
  8. Hammarström L., Persson M. A., Smith C. I. Immunoglobulin subclass distribution of human anti-carbohydrate antibodies: aberrant pattern in IgA-deficient donors. Immunology. 1985 Apr;54(4):821–826. [PMC free article] [PubMed] [Google Scholar]
  9. Hoiby N. Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Aug;82(4):541–550. [PubMed] [Google Scholar]
  10. Holby N., Olling S. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases. Acta Pathol Microbiol Scand C. 1977 Apr;85(2):107–114. [PubMed] [Google Scholar]
  11. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  12. Mikkelsen O. S. Serotyping of Pseudomonas aeruginosa. 2. Results of an O group classification. Acta Pathol Microbiol Scand B Microbiol Immunol. 1970;78(2):163–175. [PubMed] [Google Scholar]
  13. Morell A., Skvaril F., Steinberg A. G., Van Loghem E., Terry W. D. Correlations between the concentrations of the four sub-classes of IgG and Gm Allotypes in normal human sera. J Immunol. 1972 Jan;108(1):195–206. [PubMed] [Google Scholar]
  14. Moss R. B., Hsu Y. P., Van Eede P. H., Van Leeuwen A. M., Lewiston N. J., De Lange G. Altered antibody isotype in cystic fibrosis: impaired natural antibody response to polysaccharide antigens. Pediatr Res. 1987 Dec;22(6):708–713. doi: 10.1203/00006450-198712000-00020. [DOI] [PubMed] [Google Scholar]
  15. Moss R. B. Hypergammaglobulinemia in cystic fibrosis. Role of Pseudomonas endobronchial infection. Chest. 1987 Apr;91(4):522–526. doi: 10.1378/chest.91.4.522. [DOI] [PubMed] [Google Scholar]
  16. Pedersen S. S., Espersen F., Høiby N. Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol. 1987 Oct;25(10):1830–1836. doi: 10.1128/jcm.25.10.1830-1836.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Penketh A. R., Pitt T. L., Hodson M. E., Batten J. C. Bactericidal activity of serum from cystic fibrosis patients for Pseudomonas aeruginosa. J Med Microbiol. 1983 Nov;16(4):401–408. doi: 10.1099/00222615-16-4-401. [DOI] [PubMed] [Google Scholar]
  18. Perelmutter L. IgG4 and the immune system. Clin Rev Allergy. 1983 Jun;1(2):267–287. doi: 10.1007/BF02991162. [DOI] [PubMed] [Google Scholar]
  19. Pressler T., Mansa B., Jensen T., Pedersen S. S., Høiby N., Koch C. Increased IgG2 and IgG3 concentration is associated with advanced Pseudomonas aeruginosa infection and poor pulmonary function in cystic fibrosis. Acta Paediatr Scand. 1988 Jul;77(4):576–582. doi: 10.1111/j.1651-2227.1988.tb10703.x. [DOI] [PubMed] [Google Scholar]
  20. Schiøtz P. O., Egeskjold E. M., Høiby N., Permin H. Autoantibodies in serum and sputum from patients with cystic fibrosis. Acta Pathol Microbiol Scand C. 1979 Oct;87(5):319–324. [PubMed] [Google Scholar]
  21. Schiøtz P. O., Høiby N., Hertz J. B. Cross-reactions between Haemophilus influenzae and nineteen other bacterial species. Acta Pathol Microbiol Scand B. 1979 Dec;87(6):337–344. doi: 10.1111/j.1699-0463.1979.tb02448.x. [DOI] [PubMed] [Google Scholar]
  22. Schiøtz P. O., Høiby N., Hertz J. B. Cross-reactions between Staphylococcus aureus and fifteen other bacterial species. Acta Pathol Microbiol Scand B. 1979 Dec;87(6):329–336. doi: 10.1111/j.1699-0463.1979.tb02447.x. [DOI] [PubMed] [Google Scholar]
  23. Schiøtz P. O. Local humoral immunity and immune reactions in the lungs of patients with cystic fibrosis. Acta Pathol Microbiol Scand Suppl. 1981;276:1–25. [PubMed] [Google Scholar]
  24. Schumaker V. N., Calcott M. A., Spiegelberg H. L., Müller-Eberhard H. J. Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry. 1976 Nov 16;15(23):5175–5181. doi: 10.1021/bi00668a035. [DOI] [PubMed] [Google Scholar]
  25. Shryock T. R., Mollé J. S., Klinger J. D., Thomassen M. J. Association with phagocytic inhibition of anti-Pseudomonas aeruginosa immunoglobulin G antibody subclass levels in serum from patients with cystic fibrosis. J Clin Microbiol. 1986 Mar;23(3):513–516. doi: 10.1128/jcm.23.3.513-516.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stevens R., Dichek D., Keld B., Heiner D. IgG1 is the predominant subclass of in vivo- and in vitro- produced anti-tetanus toxoid antibodies and also serves as the membrane IgG molecule for delivering inhibitory signals to anti-tetanus toxoid antibody-producing B cells. J Clin Immunol. 1983 Jan;3(1):65–69. doi: 10.1007/BF00919140. [DOI] [PubMed] [Google Scholar]
  27. Szaff M., Høiby N., Flensborg E. W. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand. 1983 Sep;72(5):651–657. doi: 10.1111/j.1651-2227.1983.tb09789.x. [DOI] [PubMed] [Google Scholar]
  28. Weinberg G. A., Granoff D. M., Nahm M. H., Shackelford P. G. Functional activity of different IgG subclass antibodies against type b capsular polysaccharide of Haemophilus influenzae. J Immunol. 1986 Jun 1;136(11):4232–4236. [PubMed] [Google Scholar]
  29. Wood R. E., Boat T. F., Doershuk C. F. Cystic fibrosis. Am Rev Respir Dis. 1976 Jun;113(6):833–878. doi: 10.1164/arrd.1976.113.6.833. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES